所有图片(3)

主要文件

查看所有文档

T144

(±)-沙利度胺

Name: (±)-沙利度胺
Brand: SIGMA
Price: 1070.84 CNY
Availability: InStock

≥98%, powder

别名:

(±)-2-（2,6-二氧代-3-哌啶基）-1H-异吲哚-1,3 (2H)-二酮

登录查看公司和协议定价

选择尺寸

100 MG

CN¥1,070.84

1 G

CN¥8,487.98

CN¥1,070.84

国内现货，预计发货时间April 27, 2025详情

获取大包装报价

所有图片(3)

选择尺寸

变更视图

100 MG

CN¥1,070.84

1 G

CN¥8,487.98

About This Item

经验公式（希尔记法）:

C₁₃H₁₀N₂O₄

CAS号:

50-35-1

分子量:

258.23

EC 号:

200-031-1

MDL编号:

MFCD00153873

UNSPSC代码:

12352111

eCl@ss:

39180303

PubChem化学物质编号:

24278765

NACRES:

NA.77

CN¥1,070.84

国内现货，预计发货时间April 27, 2025详情

获取大包装报价

显示差异

1 of 4

此商品	T151	SML2686	T150
T144 (±)-Thalidomide	T151 (+)-Thalidomide	SML2686 THAL-SNS-032	T150 (−)-Thalidomide
assay ≥98%	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay >98%
form powder	form powder	form powder	form solid
solubility DMSO: 20 mg/mL, clear	solubility DMSO: 15 mg/mL, clear	solubility DMSO: 2 mg/mL, clear	solubility DMSO: soluble, H₂O: insoluble, ethanol: insoluble
originator Celgene	originator Celgene	originator -	originator Celgene
color white	color white to beige	color white to beige	color white
ligand thalidomide	ligand thalidomide	ligand pomalidomide	ligand thalidomide

应用

沙利度胺已被用于阿尔茨海默病 (AD) 小鼠模型的神经病理学研究。该研究报道，长期服用沙利度胺可引起 β-分泌酶抑制，继而减轻类淀粉样病理。[1]此外，沙利度胺也被用于评价其致畸功能。沙利度胺可影响人胚胎干细胞和诱导多能干细胞分化过程中的内胚层分化和神经发育[2]。

生化/生理作用

(±)-沙利度胺选择性抑制肿瘤坏死因子 α 的生物合成（TNF-α)。它还作为血管生成抑制剂、免疫抑制剂、镇静剂和致畸剂发挥作用。此外，已知沙利度胺在难治性多发性骨髓瘤中表现出抗肿瘤功能 [3]。

特点和优势

该化合物由 Celgene 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表，点击这里。

制备说明

沙利度胺可溶于 DMSO，浓度超过 20 mg/mL。不溶于水和乙醇。

应用

产品编号

说明

价格

警示用语：

Danger

危险声明

H301,H312,H360D

预防措施声明

P202 - P264 - P280 - P301 + P310 - P302 + P352 + P312 - P362 + P364

危险分类

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

个人防护装备

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

技术规格说明书

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.

Marzia Lazzerini et al.

JAMA, 310(20), 2164-2173 (2013-11-28)

Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead to permanent impairments. Few trials have evaluated new drugs for refractory Crohn disease in children. To determine whether thalidomide is

Antitumor activity of thalidomide in refractory multiple myeloma.

S Singhal et al.

The New England journal of medicine, 341(21), 1565-1571 (1999-11-24)

Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. Eighty-four previously

Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells.

Yoav Mayshar et al.

Journal of cellular and molecular medicine, 15(6), 1393-1401 (2010-06-22)

Teratogens are substances that may cause defects in normal embryonic development while not necessarily being toxic in adults. Identification of possible teratogenic compounds has been historically beset by the species-specific nature of the teratogen response. To examine teratogenic effects on

Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy.

Yang Yang et al.

Pharmaceutics, 15(4) (2023-04-28)

Thalidomide (THD), a synthetic derivative of glutamic acid, was initially used as a sedative and antiemetic until the 1960s, when it was found to cause devastating teratogenic effects. However, subsequent studies have clearly demonstrated the anti-inflammatory, anti-angiogenic, and immunomodulatory properties

Angiogenesis inhibitors derived from thalidomide.

Tomomi Noguchi et al.

Bioorganic & medicinal chemistry letters, 15(24), 5509-5513 (2005-09-27)

5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses

查看所有相关文献

商品

Dihydropinene Pinane Greener Solvent for Organic Synthesis

Effective in key synthesis reactions like Knoevenagel condensation, thalidomide synthesis, and Suzuki coupling for sustainable chemical transformations.

Chromatograms

HPLC Analysis of Thalidomide Enantiomers on Astec^® CHIROBIOTIC^® V2

application for HPLC

HPLC Analysis of Thalidomide Enantiomers on Astec^® CHIROBIOTIC^® V

application for HPLC

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持

主要文件

(±)-沙利度胺

≥98%, powder

选择尺寸

选择尺寸

About This Item

推荐产品

属性

ligand

方案

表单

反应适用性

颜色

溶解性

创始人

SMILES字符串

InChI

InChI key

相关类别

比较类似商品

此商品

说明

应用

生化/生理作用

特点和优势

制备说明

相关产品

应用

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

储存分类代码

WGK

个人防护装备

文件

分析证书(COA)

已有该产品？

同行评审论文

技术文章和实验方案

商品

Chromatograms

技术服务